Premium
European mitochondrial haplogroups are not associated with hepatitis C virus ( HCV ) treatment response in HIV / HCV ‐coinfected patients
Author(s) -
GuzmánFulgencio M,
Rallón N,
Berenguer J,
FernándezRodríguez A,
Soriano V,
Miralles P,
JiménezSousa MA,
Restrepo C,
López JC,
GarcíaÁlvarez M,
Aldámiz T,
Benito JM,
Resino S
Publication year - 2014
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1111/hiv.12126
Subject(s) - ribavirin , medicine , hepatitis c virus , haplogroup , genotype , hepatitis c , coinfection , viral load , human mitochondrial dna haplogroup , virology , pegylated interferon , immunology , virus , haplotype , biology , gene , genetics
Objectives Mitochondria are multifunctional organelles with a key role in the innate immune response against viral infections. Mitochondrial DNA ( mtDNA ) haplogroups have been related to AIDS progression and CD4 T ‐cell recovery in HIV ‐infected patients, and to a delay in the development of liver fibrosis in HIV /hepatitis C virus ( HCV )‐coinfected patients. We performed a study to investigate whether mtDNA haplogroups may be associated with HCV treatment response in HIV / HCV ‐coinfected patients on pegylated interferon ( pegIFN ) plus ribavirin ( RBV ). Methods We performed a retrospective study in 304 patients who completed a course of HCV therapy. mtDNA polymorphisms were genotyped using S equenom's MassARRAY platform. The interleukin‐28B ( IL‐28B ) polymorphism (rs12980275) was genotyped using the GoldenGate ® assay. Sustained virological response ( SVR ) was defined as an undetectable HCV viral load at week 24 after the end of treatment. The statistical analysis was carried out using on‐treatment data. Results The SVR rates were 52.6% (160 of 304) for all patients, and 37.8% (46 of 201) for patients with HCV genotype 1 or 4 vs. 81.4% (83 of 102) for patients with HCV genotype 2 or 3 ( P < 0.001). No significant associations were found between mtDNA haplogroup and SVR when all patients were included in the analysis and when patients were stratified by HCV genotype (i.e. those with genotypes 1/4 and 2/3 analysed separately) or IL‐28B rs12980275 genotype. Conclusions European mtDNA haplogroups were not related to HCV treatment response in HIV / HCV ‐coinfected patients on pegIFN ‐α/ RBV therapy.